Northern Ireland Faces Potential Cancer Treatment Delays Due to Radioisotope Shortage

A “severe shortage” of radioisotopes in Northern Ireland is expected to lead to the postponement or cancellation of treatments for cancer and heart patients in the region. These radioisotopes are primarily utilized for cancer diagnosis, encompassing conditions such as prostate and breast cancer. Health Minister Mike Nesbitt issued a statement indicating that this scarcity could significantly disrupt patient care over the next few weeks. The Department of Health has confirmed that this is a global shortage. Radiotherapy, also known as radioisotope therapy, involves applying small doses of radiation to gather diagnostic data on organ function within patients. It also serves therapeutic purposes. In the NHS, diagnostic processes employing radioisotopes are standard practice. Radiotherapy is also applicable for treating certain medical conditions, particularly cancer, by using radiation to impair or eliminate specific cells. The Department of Health attributes this global shortage to a temporary decrease in the production of molybdenum-99, which is essential for generating technetium-99m. The radioisotope technetium-99m is safely employed for diagnostic purposes across health and social care services. Clinicians will conduct individual patient reviews to directly discuss available options. Nesbitt stated that his department is collaborating with other UK departments to “limit” the consequences of this situation. Nesbitt remarked, “Despite efforts by my department, working in partnership with the Department of Health and Social Care (DHSC) and the other devolved administrations to limit the negative impacts of this shortage, it is expected that there will be delays to patient access to services relying on the impacted radioisotopes, potentially including cancellations.” The scarcity of molybdenum-99 stems from an abrupt global interruption in manufacturing capabilities, as several nuclear reactors responsible for producing these elements are currently non-operational. Globally, six reliable research reactors supply molybdenum-99, with none located in the UK. Some of these reactors are presently offline for crucial repair work, which the department described as essential work necessary for the safe running of the research reactors. The minister’s statement indicates that two of the affected reactors are anticipated to recommence production in the second week of November, with deliveries from them projected to restart by mid-November. The minister emphasized that the primary objective is to mitigate the impact on patients as much as feasible. He also mentioned that a National Patient Safety alert has disseminated guidance to ensure that patients with the most urgent requirements receive priority.